Previsioni del mercato dei radiofarmaci in Europa fino al 2028 – Impatto del COVID-19 e analisi regionale per tipologia (medicina nucleare diagnostica e medicina nucleare terapeutica), applicazione (oncologia, cardiologia, neurologia e altre) e utente finale (ospedali, centri di imaging, ambienti accademici e di ricerca) Centri e altri)

Introduzione al mercato

L\'Europa è composta da cinque paesi principali: Germania, Francia, Regno Unito, Italia e Spagna. La Germania è uno dei più grandi mercati di radiofarmaci. L\'ordinanza tedesca sulla radioprotezione e le linee guida per l\'ottenimento della qualifica speciale contengono prescrizioni. Nella presente ordinanza vengono elencati a titolo indicativo numeri specifici che tuttavia non costituiscono numeri minimi vincolanti. Inoltre, nel maggio 2017 è stata adottata la legge sulla radioprotezione per la protezione dal radon nelle abitazioni e migliori disposizioni in caso di emergenza. La legge sulla radioprotezione è integrata dall\'ordinanza sulla radioprotezione, entrata in vigore il 31 dicembre 2018. Inoltre, in Germania l\'assicurazione sanitaria è un aspetto importante del settore sanitario, circa 71,4 milioni di tedeschi sono coperti dall\'assicurazione sanitaria pubblica (Gesetzliche Krankenversicherung (GKV) ) quasi 8,8 milioni di tedeschi sono coperti dall\'assicurazione sanitaria privata (Private Krankenversicherung (PKV)) e dagli aiuti statali. Secondo l’Ufficio federale di statistica tedesco, i dati relativi alla spesa sanitaria annuale totale del 2019 ammontavano a 460 miliardi di dollari (410 miliardi di euro). Inoltre, gli investimenti effettuati da varie associazioni governative e non governative stanno aiutando la crescita del mercato dei radiofarmaci. Ad esempio, nel gennaio 2019, il consorzio Advancing Nuclear Medicine, con l’aiuto del Nuclear Research and Consultancy Group (NRG), ha ricevuto un sussidio di 7,7 milioni di dollari (6,8 milioni di euro) per lo sviluppo di FIELD-LAB. L\'iniziativa olandese mira ad accelerare lo sviluppo e l\'introduzione di nuovi radiofarmaci. Il campo svilupperà nuovi farmaci nucleari che, secondo le previsioni, assumeranno un ruolo crescente nel trattamento personalizzato di malattie potenzialmente letali come il cancro. Pertanto, in base ai fattori sopra menzionati, si prevede che il mercato europeo dei radiofarmaci crescerà nel periodo di previsione.

In caso di COVID-19, l\'Europa è fortemente colpita, in particolare Francia e Russia. La pandemia di COVID-19 ha cambiato profondamente le attività ospedaliere, compresa la pratica della MN in tutta Europa. È stata effettuata una ricerca bibliografica su PubMed riguardante gli studi sul COVID-19 pubblicati fino a gennaio 2021. Secondo i risultati, la pandemia ha messo a dura prova i dipartimenti di MN e una riduzione della forza lavoro è stata riscontrata in ogni centro in Europa. I dipartimenti del Nuovo Messico hanno introdotto misure di restrizione per limitare la trasmissione di COVID-19, inclusa la riprogrammazione delle procedure non ad alta priorità. Inoltre, alcuni dipartimenti hanno riscontrato un ritardo nella fornitura di radiofarmaci o nell’assistenza tecnica a causa del COVID-19. Di conseguenza, la pandemia ha comportato una significativa riduzione delle procedure diagnostiche e terapeutiche della MN e un ridotto livello di assistenza per i pazienti affetti da malattie diverse da COVID-19, come il cancro o le malattie cardiovascolari acute. La pandemia ha influenzato i flussi di lavoro in una parte sostanziale dei dipartimenti di NM. Si prevede che nuovi risultati a supporto della diagnosi di COVID-19 accelereranno la crescita dei radiofarmaci nella regione. Ad esempio, secondo lo studio di ricerca di Chentao Jin et al., pubblicato sull’European Journal of Nuclear Medicine and Molecular Imaging nel maggio 2021, si prevede che la tomografia a emissione di positroni (PET) offra alternanze fisiopatologiche di COVID-19 e faciliti l’analisi clinica gestione dei pazienti. Considerando il ruolo del PET nel COVID-19, gli studi di ricerca possono anche aprire la strada alla lotta contro altre epidemie in futuro.

Panoramica e dinamiche del mercato

Si prevede che il mercato europeo dei radiofarmaci crescerà da 1.940,54 milioni di dollari nel 2021 a 3.442,11 milioni di dollari entro il 2028; si stima che crescerà a un CAGR dell\'8,5% dal 2021 al 2028. Nelle cure personalizzate, il trattamento è individualizzato sulla base di specifici marcatori biochimici rilevati nei pazienti e delle caratteristiche della loro condizione patologica. Le tecniche di imaging identificano i pazienti per particolari terapie e ottimizzano la risposta del paziente al trattamento riducendo al minimo gli effetti collaterali. La medicina di precisione prevede l\'uso delle informazioni genomiche di un individuo per offrirgli un trattamento mirato. Negli ultimi anni, gli scienziati si stanno concentrando sulla neurogenetica pionieristica per introdurre terapie e trattamenti migliori per il cervello e i disturbi correlati. La medicina nucleare sta gradualmente guadagnando terreno e la terapia mirata con radionuclidi fornisce modalità di trattamento efficaci contro il cancro. Le ultime innovazioni riguardano l’uso di radionuclidi, dispositivi di imaging multimodale nuovi o migliorati e diversi radiofarmaci recentemente commercializzati in tutte le applicazioni mediche, in particolare cardiologia, neurologia e oncologia. Gli attuali sviluppi nei ciclotroni autoprotetti, nella progettazione di celle calde monitorate tramite video, nei bersagli migliorati e nei moduli di sintesi radiofarmaceutica PET automatizzati, basati sull\'interfaccia utente grafica (GUI) controllata dal computer, hanno rivoluzionato la tecnologia di imaging molecolare PET per la ricerca biomedica di base da realizzare medicina personalizzata basata sull’evidenza. Ulteriori progressi nei nuovi radiofarmaci PET che utilizzano moduli di sintesi microfluidica automatizzata e nanoparticelle multifunzionali miglioreranno probabilmente la scoperta di biomarcatori, la dosimetria interna, l’immunoterapia, la farmacocinetica e il tracciamento delle cellule staminali nella medicina rigenerativa. La terapia con radionuclidi recettori peptidici (PRRT) è in prima linea tra i nuovi farmaci personalizzati. Gli analoghi della somatostatina utilizzati in questa tecnica, che si legano selettivamente ai recettori cellulari sulle cellule tumorali neuroendocrine, trasportano un radionuclide di gallio che emette contemporaneamente radiazioni che uccidono i tumori e rendono gli analoghi visibili e quantificabili con la PET. L’effetto finale di un trattamento efficace e misurabile è la riduzione delle dimensioni del tumore e della riduzione dei sintomi, insieme all’arresto della progressione del tumore in molti pazienti. Pertanto, l\'uso dei farmaci nucleari nella medicina personalizzata sta emergendo come una delle principali tendenze future nel mercato europeo dei radiofarmaci.

Segmenti chiave del mercato

In termini di tipologia, il segmento della medicina nucleare diagnostica ha rappresentato la quota maggiore del mercato europeo dei radiofarmaci nel 2020. In termini di applicazione, il segmento oncologico ha detenuto una quota di mercato maggiore del mercato europeo dei radiofarmaci nel 2020. Inoltre, nel 2020 il segmento ospedaliero deteneva una quota maggiore del mercato europeo dei radiofarmaci in base all\'utente finale.

Principali fonti e aziende elencate

Alcune delle principali fonti primarie e secondarie a cui si fa riferimento per la preparazione di questo rapporto sul mercato europeo dei radiofarmaci sono siti Web aziendali, relazioni annuali, relazioni finanziarie, documenti governativi nazionali e database statistici, tra gli altri. Le principali aziende elencate nel rapporto sono Advanced Accelerator Applications; Bayer AG; Bracco Imaging SpA; Cardinale Salute Inc; Curio; ECZACIBAČI MONROL NUCLEAR PRODUCTS CO.; ELETTRICO GENERALE; Lantheus Medical Imaging, Inc.; Nordione; e RADIOISOTOPI NTP.

Rapporto sui motivi per acquistare

Comprendere il panorama del mercato europeo dei radiofarmaci e identificare i segmenti di mercato che hanno maggiori probabilità di garantire un forte rendimento
Mantenere un vantaggio comprendendo il panorama competitivo in continua evoluzione per il mercato europeo dei radiofarmaci
Pianificare in modo efficiente fusioni e acquisizioni e accordi di partnership nel mercato europeo dei radiofarmaci identificando i segmenti di mercato con le vendite probabili più promettenti
Aiuta a prendere decisioni aziendali consapevoli grazie a un\'analisi perspicace e completa delle prestazioni di mercato dei vari segmenti dal mercato europeo dei radiofarmaci
Ottenere previsioni sui ricavi di mercato per vari segmenti dal 2021 al 2028 nella regione europea.

Segmentazione del mercato dei radiofarmaci in Europa

Mercato dei radiofarmaci in Europa - Per tipo

Medicina nucleare diagnostica
- SPECT
- PET
Medicina nucleare terapeutica
- Emettitori alfa
- Emettitori beta
- Isotopi della brachiterapia

< p>Mercato europeo dei radiofarmaci - Per applicazione

Oncologia
Cardiologia
Neurologia
Altro

Mercato europeo dei radiofarmaci - Per utente finale

Ospedali
Centri di imaging
Centri accademici e di ricerca
Altri

Mercato radiofarmaceutico in Europa: per paese

Mercato europeo dei radiofarmaci - Profili aziendali

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Radiopharmaceuticals Market – By Type

1.3.2 Europe Radiopharmaceuticals Market – By Application

1.3.3 Europe Radiopharmaceuticals Market – By End User

1.3.4 Europe Radiopharmaceuticals Market– By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Radiopharmaceuticals Market– Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Radiopharmaceuticals Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Use of Alpha Radio Immunotherapy for Cancer Treatment

5.1.2 Rising Advancements in Nuclear Imaging Techniques

5.2 Market Restraints

5.2.1 Availability of Alternatives

5.3 Market Opportunities

5.3.1 Escalating Growth in Emerging Countries

5.4 Future Trends

5.4.1 Suring Use of Nuclear Medicines for Personalized Treatment

5.5 Impact Analysis

6. Radiopharmaceuticals Market– Europe Analysis

6.1 Europe Radiopharmaceuticals Market Revenue Forecast and Analysis

7. Europe Radiopharmaceuticals Market Analysis – By Type

7.1 Overview

7.2 Europe Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)

7.3 Diagnostic Nuclear Medicine

7.3.1 Overview

7.3.2 Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.3.3 SPECT

7.3.3.1 Overview

7.3.3.2 SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.3.4 PET

7.3.4.1 Overview

7.3.4.2 PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Therapeutic Nuclear Medicine

7.4.1 Overview

7.4.2 Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3 Alpha Emitters

7.4.3.1 Overview

7.4.3.2 Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4 Beta Emitters

7.4.4.1 Overview

7.4.4.2 Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.5 Brachytherapy Isotopes

7.4.5.1 Overview

7.4.5.2 Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8. Europe Radiopharmaceuticals Market Analysis – By Application

8.1 Overview

8.2 Europe Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)

8.3 Oncology

8.3.1 Overview

8.3.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Cardiology

8.4.1 Overview

8.4.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Neurology

8.5.1 Overview

8.5.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Radiopharmaceuticals Market Analysis – By End User

9.1 Overview

9.2 Europe Radiopharmaceuticals Market Share, by End User, 2021 and 2028, (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Imaging Centres

9.4.1 Overview

9.4.2 Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Academic and Research Centers

9.5.1 Overview

9.5.2 Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Others

9.6.1 Overview

9.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Radiopharmaceuticals Market – Country Analysis

10.1 Europe: Radiopharmaceuticals Market

10.1.1 Overview

10.1.2 Europe: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)

10.1.2.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.1.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.1.2 Germany: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.1.2.1 Germany: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.1.2.2 Germany: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.1.3 Germany: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.1.4 Germany: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.2 France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.2.1 France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.2.2 France: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.2.2.1 France: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.2.2.2 France: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.2.3 France: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.2.4 France: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.3 UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.3.1 UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.3.2 UK: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.3.2.1 UK: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.3.2.2 UK: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.3.3 UK: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.3.4 UK: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.4 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.4.1 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.4.2 Italy: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.4.2.1 Italy: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.4.2.2 Italy: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.4.3 Italy: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.4.4 Italy: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.5 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.5.1 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.5.2 Spain: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.5.2.1 Spain: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.5.2.2 Spain: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.5.3 Spain: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.5.4 Spain: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

10.1.2.6 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.6.1 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

10.1.2.6.2 Rest of Europe: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)

10.1.2.6.2.1 Rest of Europe: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.6.2.2 Rest of Europe: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)

10.1.2.6.3 Rest of Europe: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)

10.1.2.6.4 Rest of Europe: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)

11. Impact Of COVID-19 Pandemic on Europe Radiopharmaceuticals Market

11.1 Europe: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Cardinal Health Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Curium

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 GENERAL ELECTRIC

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Lantheus Medical Imaging, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bayer AG

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Bracco Imaging S.p.A

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Nordion

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 NTP RADIOISOTOPES

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Advanced Accelerator Applications

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES

Table 1. Europe Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Table 2. Germany: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 3. Germany Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 4. Germany Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 5. Germany: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 6. Germany: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 7. France: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 8. France Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 9. France Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 10. France: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 11. France: Radiopharmaceuticals Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 12. UK: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 13. UK Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 14. UK Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 15. UK: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 16. UK: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 17. Italy: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 18. Italy Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 19. Italy Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 20. Italy: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 21. Italy: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 22. Spain: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 23. Spain Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 24. Spain Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 25. Spain: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 26. Spain: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 27. Rest of Europe: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 28. Rest of Europe Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 29. Rest of Europe Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)

Table 30. Rest of Europe: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 31. Rest of Europe: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 32. Recent Inorganic Growth Strategies

Table 33. Recent Organic Growth Strategies

Table 34. Glossary of Terms

LIST OF FIGURES

Figure 1. Europe Radiopharmaceuticals Market Segmentation

Figure 2. Europe Radiopharmaceuticals Market Segmentation, By Country

Figure 3. Europe Radiopharmaceuticals Market Overview

Figure 4. Diagnostic Nuclear Medicine Segment Held the Largest Share of the Market in 2021

Figure 5. The UK to Show Significant Growth During Forecast Period

Figure 6. Europe PEST Analysis

Figure 7. Europe Radiopharmaceuticals Market Impact Analysis of Drivers and Restraints

Figure 8. Europe Radiopharmaceuticals Market– Revenue Forecast and Analysis

Figure 9. Europe Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)

Figure 10. Europe Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11. Europe SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. Europe PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. Europe Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. Europe Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15. Europe Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. Europe Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. Europe Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)

Figure 18. Europe Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19. Europe Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. Europe Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. Europe Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. Europe Radiopharmaceuticals Market Share, by End User, 2021 and 2028 (%)

Figure 23. Europe Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. Europe Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Europe Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Europe Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Europe: Radiopharmaceuticals Market, by Key Country – Revenue (2021) (USD Million)

Figure 28. Europe: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)

Figure 29. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 30. France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 31. UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 32. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 33. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 34. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)

Figure 35. Impact of COVID-19 Pandemic in European Country Markets

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe radiopharmaceuticals market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the radiopharmaceuticals market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Europe Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software and Serv..	May 2022
Europe Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Electric P..	May 2022
Europe In-Office Teeth Whitening Products Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Double-Syringe Mixing Configurat..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000

$3000

GET FREE SAMPLE PDF

Inquire before Buying Inquire for Discount

Subscription Member Price: FREE

Get Subscription

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

Request for Free Sample